中晚期肝癌临床治疗进展

李焱; 程朋

doi:10.3969/j.issn.1001-5256.2014.03.009

中晚期肝癌临床治疗进展

DOI: 10.3969/j.issn.1001-5256.2014.03.009

李焱,
程朋

成都军区总医院肿瘤诊治中心

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3608
- HTML全文浏览量: 12
- PDF下载量: 862
- 被引次数: 0
出版历程
- 出版日期: 2014-03-20

Advances in treatment of advanced hepatocellular cancer

Li Yan,
Cheng Peng

摘要

摘要:
肝癌的发病隐匿,早期诊断困难,进展较快,临床上仅有不足30%的患者就诊时可获得手术治疗的机会,因此非手术疗法是中晚期肝癌的主要治疗方式。总结了几种主要的非手术治疗方式———血管介入治疗、分子靶向和化疗药物治疗、放疗以及局部消融治疗在肝癌治疗中的地位。认为尽管综合治疗已成为肝癌治疗的共识,但是他们在综合治疗中的地位及次序等仍未形成共识,还需要进行更多的临床研究,从而为中晚期肝癌患者的治疗提供更好的选择。
- 肝肿瘤 /
- 放射摄影术,介入性 /
- 药物疗法 /
- 放射疗法 /
- 消融治疗 /
- 综述
Abstract:
Hepatocellular cancer ( HCC) is characterized by insidious onset, difficult early diagnosis, and rapid progression, and less than 30% of patients have the chance of being surgically treated when diagnosed with this disease. Therefore, non- surgical treatment is the main treatment modality for advanced HCC. The roles of vascular interventional therapy, molecular targeted therapy, chemotherapy, radiotherapy, and local ablation in the treatment of HCC are summarized. Although we have reached the agreement that comprehensive treatment is the best way for HCC, consensus has not been reached on the roles and order of these non- surgical therapies in comprehensive treatment. More clinical studies are needed to provide a better choice of treatment for patients with advanced HCC.
- liver neoplasms /
- radiography, interventional /
- drug therapy /
- radiotherapy /
- ablation treatment /
- review

HTML全文

参考文献(28)

[1]CHOI JW, PARK JY, AHN SH, et al.Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection[J].Am J Clin Oncol, 2009, 32 (6) :564-549.

[2]LLOVET JM, REAL MI, MONTANA X, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet, 2002, 359:1734-1739.

[3]CAMMO C, SCHEPIS F, ORLANDO A, et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials[J].Radiology, 2002, 224 (1) :47-54.

[4]BEFELER AS.Chemoembolization and bland embolization:a critical appraisal[J].Clin Liver Dis, 2005, 9 (2) :287-300.

[5]TAKAYASU K, ARII S, KUDO M, et al.Superselective transarterial chemoembolization for hepatocellular carcinoma.Validation of treatment algorithm proposed by Japanese guidelines[J].J Hepatol, 2012, 56 (4) :886-892.

[6]LO CM, NGAN H, TSO WK, et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology, 2002, 35 (5) :1164-1171.

[7]SANGRO B, BIBAO JI, BOAN J, et al.Radioembolization using90Y-resin microspheres for patients with advanced hepatocellular carcinoma[J].Int J Radiat Oncol Biol Phys, 2006, 66 (3) :792-800.

[8]SANGRO B, CARPANESE L, CIANNI R, et al.Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across barcelona clinic liver cancer stages:a european evaluation[J].Hepatology, 2011, 54 (3) :868-878.

[9]CARR BI, KONDRAQUNTA V, BUCH SC, et al.Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microspheres treatments in unresectable hepatocellular carcinoma:a two-cohort study[J].Cancer, 2010, 116 (5) :1305-1314.

[10]LAMMER J, MALAGARI K, VOGL T, et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study[J].Cardiovasc Intervent Radiol, 2010, 33 (1) :41-52.

[11]LOVET JM, RICCI S, MAZZAFERRO V, et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.

[12]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebocontrolled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.

[13]RICHLY H, KUPSCH P, PASSAGE K, et al.Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer[J].Int J Clin Pharmacol Ther, 2004, 42 (11) :650-651.

[14]DEL PRETE S, MONTELLA L, ADDED R, et al.Sorafenib plus long acting octreotide in advanced hepatocellular carcinoma.Preliminary results of a multicenter ongoing study[J].J Clin Oncol, 2008, 26 (19) :15624.

[15]MOORE M, HIRTE HW, SIU L, et al.Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors[J].Ann Oncol, 2005, 16 (10) :1688-1694.

[16]STRUMBERG D, VOLIOTIS D, MOELLER JG, et al.Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors[J].Int J Clin Pharmacol Ther, 2002, 40 (12) :580-581.

[17]FORNER A, LLOVET JM, BRUIX J.Sunitinib and the benefits of a negative study[J].Lancet Oncol, 2009, 10 (8) :743-744.

[18]GONG XL, QIN SK, WANG YJ, et al.Effcicacy of FOLFOX4 regimen in treatment of advanced hepatocellular carcinoma:a multicenter phaseⅡtrial[J].Chin J New Drugs, 2011, 20 (17) :1673-1677. (in Chinese) 龚新雷, 秦叔逵, 王雅杰, 等.FOLFOX4方案治疗晚期肝细胞癌的多中心Ⅱ期临床研究[J].中国新药杂志, 2011, 20 (17) :1673-1677.

[19]LIANG SX, ZHU XD, LU HJ, et al.Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma[J].Cancer, 2005, 103 (10) :2181-2188.

[20]JANG JW, KAY CS, YOU CR, et al.Simultaneous multitarget irr adiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases[J].Int J Radiat Onco l Biol Phys, 2009, 74 (2) :412-418.

[21]KWON JH, BAE SH, KIM JY, et al.Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therpy or surgical resection.Stereotactic radiothreapy for liver cancer[J].BMC Cancer, 2010, 10:475.

[22]MIZUMOTO M, TOKUUYE K, SUGAHARA S, et al.Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus:report of three cases[J].Jpn J Clin Onco l, 2007, 37 (6) :459-462.

[23]TAURA K, IKAI I, HATANO E, et al.Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection:an analysis of 610 patients over 16 years old[J].Ann Surg, 2006, 244 (2) :265-273.

[24]CHOI D, LIM HK, RHIM H, et al.Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy:long-term results and prognostic factors[J].Ann Surg Oncol, 2007, 14 (8) :2319-2329.

[25]LIANG HH, CHEN MS, PENG ZW, et al.Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma:a retrospective study[J].Ann Surg Oncol, 2008, 15 (12) :3484-3493.

[26]GOTO E, TATEISHI R, SHIINA S, et al.Hemorrhagic complications of percutaneous radiofrequency ablation for liver tumors[J].Clin Gastroenterol, 2010, 44 (5) :374-380.

[27]BECKER G, SOEZGEN T, OLSCHEWSKI M, et al.Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma[J].World J Gastroenterol, 2005, 11 (39) :6104-6109.

[28]ZHANG YJ, LIANG HH, CHEN MS, et al.Hepatocellularcarcinoma treated with radio frequency ablation with or without ethanol injection:a pro spective randomizedtrial[J].Radiology, 2007, 244 (2) :599-607.

施引文献

资源附件(0)

访问统计